Amgen AMGN financials

Healthcare & Pharma · Statements and segments from its SEC filings, 2007 to 2025.

Amgen revenue, gross and operating margin, net income, free cash flow, cash and debt by quarter and by fiscal year, and revenue by segment, read from the company's own filings with the US Securities and Exchange Commission. Free to everyone; the Risk & Quality report that scores the company is the paid step.

  • revenue by product: Product sales, Other revenues, Other products, Enbrel, Neulasta® (pegfilgrastim), Prolia, Otezla, Aranesp, Xgeva, Sensipar®/Mimpara® (cinacalcet), Nplate, Repatha, Kyprolis, EPOGEN® (epoetin alfa), Evenity, Tepezza, Tezspire, Blincyto, Krystexxa, Vectibix, Uplizna, Imdelltra/Imdylltra
  • revenue by region: US, ROW

The numbers

Annual figures

LineFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$23B$22.8B$23.7B$23.4B$25.4B$26B$26.3B$28.2B$33.4B$36.8B
Gross profit$18.8B*$18.8B*$19.6B*$19B*$19.3B*$19.5B*$19.9B*$19.7B*$20.6B*$24.7B*
Operating income$9.8B$10B$10.3B$9.7B$9.1B$7.6B$9.6B$7.9B$7.3B$9.1B
Net income$7.7B$2B$8.4B$7.8B$7.3B$5.9B$6.6B$6.7B$4.1B$7.7B
EPS (diluted)$10.24$2.69$12.62$12.88$12.31$10.28$12.11$12.49$7.56$14.23
Operating cash flow$10.4B$11.2B$11.3B$9.2B$10.5B$9.3B$9.7B$8.5B$11.5B$10B
Free cash flow$9.6B*$10.5B*$10.6B*$8.5B*$9.9B*$8.4B*$8.8B*$7.4B*$10.4B*$8.1B*
Cash & equivalents$3.2B$3.8B$6.9B$6B$6.3B$8B$7.6B$10.9B$12B$9.1B
Total debt$34.6B$35.3B$33.9B$29.9B$33B$33.3B$38.9B$64.6B$60.1B$54.6B
Gross margin81.9%82.2%82.7%81.4%75.8%75.2%75.7%70.0%61.5%67.2%
Operating margin42.6%43.6%43.2%41.4%35.9%29.4%36.3%28.0%21.7%24.7%
Net margin33.6%8.7%35.3%33.6%28.6%22.7%24.9%23.8%12.2%21.0%

Latest quarters

LineQ3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Revenue$8.5B$9.1B*$8.1B$9.2B$9.6B$9.9B*$8.6B$10.1B
Gross profit$5.2B*$6B*$5.2B*$6.2B*$6.5B*$6.9B*$5.9B*$7.2B*
Operating income$2B$2.3B*$1.2B$2.7B$2.5B$2.7B*$2.7B$3.5B
Net income$2.8B$627M*$1.7B$1.4B$3.2B$1.3B*$1.8B$2.4B
EPS (diluted)$5.22$1.16*$3.20$2.65$5.93$2.46*$3.34$4.37
Operating cash flow$3.6B*$4.8B*$1.4B$2.3B*$4.7B*$1.6B*$2.2B$4B*
Free cash flow$3.3B*$4.4B*$980M*$1.9B*$4.2B*$961M*$1.5B*$3.5B*
Cash & equivalents$9B$12B$8.8B$8B$9.4B$9.1B$12B$14B
Total debt$60.4B$60.1B$57.4B$56.2B$54.6B$54.6B$57.3B$57.3B
Gross margin61.1%65.7%63.6%67.2%67.8%69.8%68.2%72.0%
Operating margin24.1%25.4%14.5%28.9%26.4%27.6%30.9%35.0%
Net margin33.3%6.9%21.2%15.6%33.7%13.5%21.1%23.6%

Revenue by product

LineFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Product sales------$26.9B$32B$35.1B
Other revenues$1.1B$1.2B$1.2B$1.2B$1.7B$1.5B$1.3B$1.4B$1.6B
Other products$2.6B$3.3B$5B$5.4B$5.3B$5.6B---
Enbrel$5.4B$5B$5.2B$5B$4.5B$4.1B---
Neulasta® (pegfilgrastim)$4.5B$4.5B$3.2B$2.3B$1.7B$1.1B---
Prolia$2B$2.3B$2.7B$2.8B$3.2B$3.6B---
Otezla---$2.2B$2.2B$2.3B---
Aranesp$2.1B$1.9B$1.7B$1.6B$1.5B$1.4B---
Xgeva$1.6B$1.8B$1.9B$1.9B$2B$2B---
Sensipar®/Mimpara® (cinacalcet)$1.7B$1.8B$551M------
Nplate---$850M$1B$1.3B---
Repatha---$887M$1.1B$1.3B---
Kyprolis$835M$968M$1B$1.1B$1.1B$1.2B---
EPOGEN® (epoetin alfa)$1.1B$1B$867M------
Evenity---$350M$530M$787M---

Revenue by region

LineFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
US$18B$18.4B$17.2B$18.5B$18.2B$18.6B$19.8B$23.9B$26.4B
ROW$4.8B$5.4B$6.1B$6.9B$7.8B$7.7B$8.4B$9.6B$10.3B

* derived: a fourth quarter as the year less the three filed quarters, or a remainder as the total less the parts. All other figures are as filed.

About this page

Every figure on this page is read from Amgen's own SEC filings: the statement lines from the SEC's XBRL company-facts feed, the revenue splits from the segment and revenue notes of each 10-K and 10-Q. Nothing is typed in or estimated. The cache refreshes daily.

Read the Risk & Quality report on Amgen or see all companies.

More in Healthcare & Pharma